Tests peginterferon alfa-2b for chronic hepatitis B in adults
Tests peginterferon alfa-2b with an immune treatment in adults with chronic hepatitis B.
Plain-language title generated from the registry record
Registry title: Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06777173, who can take part
Where in China
- Beijing Ditan HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Ditan Hospital
- Trial code
- NCT06777173
- Record updated
- 15 January 2025
- Original description
Establish a study cohort of adult chronic hepatitis B antiviral treatment based on the principle of responseguidedtreatment (RGT) corresponding to the child cohort, analyze the clinical cure factors of IC and IT stage adults chronic hepatitis B, and optimize the antiviral treatment plan. To determine the safety and efficacy of PD-1 antibody combined with Peg-FNa-2b in the treatment of adult NAs patients with CHB advantage.Read full original descriptionShow less
Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for Chronic Hepatitis B in Adults
Establish a study cohort of adult chronic hepatitis B antiviral treatment based on the principle of responseguidedtreatment (RGT) corresponding to the child cohort, analyze the clinical cure factors of IC and IT stage adults chronic hepatitis B, and optimize the antiviral treatment plan. To determine the safety and efficacy of PD-1 antibody combined with Peg-FNa-2b in the treatment of adult NAs patients with CHB advantage.
Inclusion: Age 18-65 years old；; Meet the 2022 Chronic Hepatitis B Guidelines definition of chronic HBV infection: HBsAg and/or HBVDNA positive >6 months;；; Immune clearance period: HBeAg positive, HBVDNA positive, ALT>40U/L; Newly treated patients; Willing to sign informed consent.
Exclusion: Alcoholics or drug users who have not abstained; Patients with HAV, HCV, HEV infection and autoimmune liver disease; Pregnant and lactating women and patients who plan to give birth in the near future; Patients with cirrhosis or liver cancer indicated by imaging or liver hardness testing; A history of serious heart disease, including unstable or uncontrolled heart disease within the last 6 months; Have a mental illness or history of mental illness; Have uncontrolled seizures; Have uncontrolled diabetes, hypertension, thyroid disease, retinopathy, autoimmune disease, etc.